Showing results (71-80 of 96) with videos related to
Sort By:
Pageof 10
Molecular Cancer|June 6, 2014
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistanceDaniele Cretella, Francesca Saccani, Federico Quaini, et al.Journal of Thoracic Disease|April 10, 2019
Risk of recurrence in stage I adenocarcinoma of the lung: a multi-institutional study on synergism between type of surgery and type of nodal stagingFrancesco Guerrera, Filippo Lococo, Andrea Evangelista, et al.Journal of Thoracic Imaging|August 27, 2024
Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint InhibitorsMaurizio Balbi, Giulia Mazzaschi, Ludovica Leo, et al.Tumori|March 18, 2021
Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patientsFrancesca Trentini, Giulia Mazzaschi, Gianluca Milanese, et al.Lung Cancer (Auckland, N.Z.)|July 4, 2025
Genomic and Transcriptomic Profiles in Smokers and Never-Smokers Lung Squamous Cell Carcinoma PatientsMatteo Canale, Alessandra Virga, Davide Angeli, et al.Clinical Lung Cancer|April 15, 2023
Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative ResultsFilippo Lococo, Alessandra Cancellieri, Marco Chiappetta, et al.Neoplasia (New York, N.Y.)|July 14, 2017
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma CellsMara A Bonelli, Graziana Digiacomo, Claudia Fumarola, et al.Molecular Cancer|December 14, 2012
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell linesAndrea Cavazzoni, Roberta R Alfieri, Daniele Cretella, et al.European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|January 19, 2018
Blood and lymphatic vessels contribute to the impact of the immune microenvironment on clinical outcome in non-small-cell lung cancerGiovanna Armani, Denise Madeddu, Giulia Mazzaschi, et al.Immunotherapy|August 20, 2025
Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapyGiulia Mazzaschi, Roberto Rosati, Simona D'Agnelli, et al.Pageof 10